Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Eli Lilly & Co. on Tuesday will ask the Seventh Circuit to set a standard process for determining when workers can pool ...

(Reuters) -Eli Lilly said on Monday it would buy cancer ... As part of the deal, Scorpion will spin out a new entity to hold its employees and non-PI3K pipeline assets. The new, independent ...